Recorded Presentations from the NCCN 2024 Nursing Program: Advancing Oncology Nursing™
This program will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Presentations will focus on current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting.
Target Audience
This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
Overall Learning Objectives
• Discuss advances in the treatment of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
• Review issues related to Updates on Safe Handling; A Model for Responding to Chemotherapy Infusion Hypersensitivity Reactions; Management of Colorectal Cancer; Bispecific Antibodies: A New Frontier in Immunotherapy; Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas; Pain Management in Oncology; and Cancer Care of the LGBTQ+ Community: Nursing Perspectives.
Updates on Safe Handling
• Review the health risks for nurses associated with handling hazardous drugs.
• Discuss the current standards for the safe handling of hazardous drugs.
• Identify barriers to nursing compliance with safe handling standards.
A Model for Responding to Chemotherapy Infusion Hypersensitivity Reactions
• Review the incidence, clinical features and complications associated with hypersensitivity reactions.
• Discuss best practices in the management of hypersensitivity reactions.
• Discuss the implementation of a hypersensitivity algorithm and the practice implications.
Management of Colorectal Cancer
• Describe the importance of diagnostic evaluation and impact on treatment approaches.
• Summarize new advancements in the management of colorectal cancer.
• Provide examples of supportive care issues and related interventions for patients with colorectal cancers.
Bispecific Antibodies: A New Frontier in Immunotherapy
• Discuss the unique function of bispecific antibodies.
• Review symptom management of recently approved agents.
• Provide common challenges with coordination of care and logistics with these agents.
Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas
• Outline the current treatment approach for transformed indolent lymphomas.
• Summarize the evidence from clinical trials supporting the use of CAR T-cell therapy and other novel chemotherapy-free options for the management of transformed indolent lymphomas.
• Review the unique toxicities associated with novel agents including CAR T-cell therapy and develop an effective supportive care plan for the prevention and management of treatment-related side effects.
Pain Management in Oncology
• Describe the role of non-opioid analgesics in the management of cancer pain.
• Review the principles and utilization of opioids in moderate to severe cancer pain.
• Elaborate on medical management strategies of opioid-induced adverse effects.
Cancer Care of the LGBTQ+ Community: Nursing Perspectives
• Review the incidence of cancer in the LGBTQ+ patient population.
• Discuss the barriers to care for LGBTQ+ patients.
• Identify nursing competencies to improve the care of LGBTQ+ patients experiencing cancer.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Robin R. Klebig, MSN, APRN, AOCNP
Marylou Nesbitt, MS, RN, AOCN
Carey Ramirez, ANP-C, ACHPN
Diego Rodriguez, MSN, RN, OCN
Kaylee Timlin, MSN, RN, AGACNP-BC
Amanda E. Visnick, RN, BSN, OCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Megan Corbett, MSN, RN, NPD-BC, OCN
PHARMACOSMOS A/S: Honoraria
MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD Biosciences: Consulting Fee; Honoraria
Aileen Tangonan MacAndrew, RN, MSN, NP-C
Taiho Pharmaceuticals Co., Ltd.: Product/Speakers Bureau
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
These activities are approved for nursing contact hours. Complete accreditation information is provided before each individual educational activity.
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing